A RANDOMİZED CONTROLLED TRİAL COMPARİNG THE EFFECTİVENESS OF MYOFASCİAL RELEASE, LOW-LEVEL LASER THERAPY, AND PELOİD THERAPY İN PATİENTS DİAGNOSED WİTH MİLD TO MODERATE CARPAL TUNNEL SYNDROME

November 12, 2026 updated by: RAİKAN BÜYÜKAVCI, Konya Beyhekim Training and Research Hospital

This randomized controlled trial aims to compare the effectiveness of low-level laser therapy (LLLT), myofascial release (MFR), and peloid therapy in patients diagnosed with mild to moderate carpal tunnel syndrome (CTS). A total of 84 eligible participants aged 18-65 years will be randomly assigned to one of three treatment groups. Group 1 (LLLT): Patients will receive low-level laser therapy 5 days a week for 3 weeks (total 15 sessions). Group 2 (Myofascial Release): Patients will receive manual myofascial release therapy 3 days a week for 5 weeks. Group 3 (Peloid Therapy): Patients will receive peloid (mud) therapy at 45°C for 20 minutes, 5 days a week for 3 weeks (total 15 sessions). Clinical evaluations will be performed at baseline, at the end of the treatment (15th session), and at the 12-week follow-up. The primary outcome measures are the Boston Carpal Tunnel Questionnaire (BCTSQ) and Jamar dynamometer grip strength. Secondary outcome measures include ultrasonographic median nerve cross-sectional area (CSA) and electrophysiological nerve conduction studies (EMG).

Study Overview

Detailed Description

Background and Rationale: Carpal Tunnel Syndrome (CTS) is the most common peripheral nerve entrapment syndrome, resulting from the compression of the median nerve at the wrist. Conservative treatment options play a primary role in the management of mild to moderate CTS, aiming to reduce pain, alleviate symptoms, and improve functional status without immediate surgical intervention. This single-center, randomized controlled trial aims to compare the clinical and objective effectiveness of three distinct conservative modalities-low-level laser therapy (LLLT), myofascial release (MFR), and peloid therapy-routinely used in clinical practice. Study Design and Participants: A total of 84 male and female patients aged 18-65 years diagnosed with mild to moderate CTS at the Department of Physical Medicine and Rehabilitation, SBÜ Konya Beyhekim Training and Research Hospital, will be enrolled. Participants will be randomized into three intervention groups using a computer-generated randomization scheme. Intervention Groups:• Group 1 (Low-Level Laser Therapy - LLLT): Patients will receive LLLT administered by an experienced technician 5 days a week for 3 weeks (15 sessions in total). Treatment will be applied using a gallium-aluminum-arsenide (GaAlAs) diode laser emitting infrared light at an 860 nm wavelength, 1 kHz frequency, and 100 mW power output. The dosage will be 3.6 J/cm2, applied perpendicular to the skin over an area of approximately 15-20 cm2 for 40 seconds, with a total session duration of 120 seconds. • Group 2 (Myofascial Release - MFR): Patients will receive manual myofascial release therapy performed by an experienced physician 3 days a week for 5 weeks (15-30 minutes per session). The intervention will involve identifying tight muscle bands and trigger points in the wrist and forearm, applying direct pressure, gentle stretching, and implementing specific nerve and tendon gliding exercises. • Group 3 (Peloid Therapy): Patients will receive medical peloid therapy (sourced from Köyceğiz, Muğla, rich in organic/inorganic substances and humic acid) applied 5 days a week for 3 weeks (15 sessions in total). A 1.5-2 cm thick layer of peloid heated to 45°C will be applied to the affected extremity, wrapped with a plastic bag and towel for 20 minutes, followed by gentle cleansing with warm water. Outcome Measures and Evaluation Schedule: Evaluations will be performed at baseline, at the end of the treatment (15th session), and at the 12-week follow-up. • Primary Outcome Measures: Symptom severity and functional status assessed via the Boston Carpal Tunnel Questionnaire (BCTSQ), and maximum grip strength measured objectively using a Jamar dynamometer. • Secondary Outcome Measures: Ultrasonographic assessment of the median nerve cross-sectional area (CSA) at the wrist level and electrophysiological nerve conduction studies (EMG) performed at the 12-week control.

Study Type

Interventional

Enrollment (Estimated)

88

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: RAİKAN BÜYÜKAVCI, MD, Prof.
  • Phone Number: 4042 +90-0332-224-30-00
  • Email: rsoydemir@yahoo.com

Study Locations

      • Konya, Turkey (Türkiye), 42000
        • Recruiting
        • University of Health Sciences, Konya Beyhekim Training and Research Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age between 18 and 65 years.
  • Diagnosis of mild or moderate Carpal Tunnel Syndrome (CTS) confirmed by electrophysiological tests (EMG).
  • Symptoms persisting for at least 3 months.
  • No prior history of surgical treatment for carpal tunnel syndrome.

Exclusion Criteria:

  • Severe carpal tunnel syndrome detected by electrophysiological tests.
  • History of severe trauma, fracture, or surgery in the same extremity within the last 6 months.
  • Having received physical therapy (TENS, laser, exercise, etc.) or injection therapy for CTS within the last 3 months.
  • Pregnant or lactating women.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Low-Level Laser Therapy (LLLT) Group

Patients in this group will receive low-level laser therapy (LLLT) administered 5 days a week for 3 weeks, totaling 15 sessions. The treatment will be applied using a gallium-aluminum-arsenide (GaAlAs) diode laser emitting infrared light.

Low-level laser therapy administered 5 days a week for 3 weeks (total 15 sessions) using a GaAlAs diode laser.

Active Comparator: Myofascial Release (MFR) Group

Patients in this group will receive manual myofascial release (MFR) therapy performed 3 days a week for 5 weeks. The intervention involves identifying tight muscle bands and trigger points in the wrist and forearm, applying direct manual pressure, gentle stretching, and specific nerve and tendon gliding exercises.

Manual myofascial release therapy performed 3 days a week for 5 weeks, including trigger point release and neural/tendon gliding exercises.

Active Comparator: Peloid Therapy Group

Patients in this group will receive medical peloid (mud) therapy applied 5 days a week for 3 weeks, totaling 15 sessions. A 1.5-2 cm thick layer of peloid heated to 45°C will be applied to the affected extremity, wrapped for 20 minutes, and then gently cleansed with warm water.

Medical peloid therapy applied at 45°C for 20 minutes, 5 days a week for 3 weeks (total 15 sessions).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Boston Carpal Tunnel Questionnaire (BCTSQ) Score
Time Frame: Baseline, at the end of treatment (week 3 / 15th session), and at the 12-week follow-up.

Assessment of symptom severity and functional status using the Boston Carpal Tunnel Questionnaire (BCTSQ), which consists of a Symptom Severity Scale (11 items) and a Functional Status Scale (8 items), scored from 1 (best) to 5 (worst).

Baseline, at the end of treatment (week 3 / 15th session), and at the 12-week follow-up.
Maximum Grip Strength
Time Frame: Baseline, at the end of treatment (week 3 / 15th session), and at the 12-week follow-up.

Objective measurement of maximum hand grip strength evaluated using a Jamar dynamometer (recorded in kilograms or pounds).

Baseline, at the end of treatment (week 3 / 15th session), and at the 12-week follow-up.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Ultrasonographic Median Nerve Cross-Sectional Area (CSA)
Time Frame: Baseline and at the 12-week follow-up.

Assessment of the median nerve cross-sectional area (CSA) at the wrist level using high-resolution ultrasonography to evaluate structural changes and reduction in nerve swelling.

Baseline and at the 12-week follow-up.
Electrophysiological Nerve Conduction Parameters (SNCV, SNAP, CMAP, DML)
Time Frame: Baseline and at the 12-week follow-up.

Evaluation of median nerve conduction characteristics, including sensory nerve conduction velocity (SNCV), sensory nerve action potential (SNAP) amplitude, compound muscle action potential (CMAP) amplitude, and distal motor latency (DML).

Baseline and at the 12-week follow-up.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: ERDİ İNCİGÜZ, M.D., University of Health Sciences, Konya Beyhekim Training and Research Hospital
  • Study Chair: RAİKAN BÜYÜKAVCI, MD, Prof., University of Health Sciences, Konya Beyhekim Training and Research Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 5, 2026

Primary Completion (Estimated)

March 1, 2027

Study Completion (Estimated)

July 1, 2027

Study Registration Dates

First Submitted

November 12, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Prerequisites / What data will be shared:De-identified individual participant data (including demographic data, baseline and follow-up Boston Carpal Tunnel Questionnaire scores, Jamar grip strength measurements, ultrasonographic median nerve cross-sectional area [CSA] values, and electrophysiological nerve conduction parameters) underlying the results reported in the future publication will be shared.Supporting Documents:Study Protocol and Informed Consent Form will also be available upon request.Time Frame:Available beginning 3 months and ending 5 years following article publication.Access Criteria:Requests should be directed to the corresponding author via email. Data will be shared with researchers whose proposed use of the data has been approved by the principal investigator and institutional ethics committee, provided that a signed data access agreement is established.

IPD Sharing Time Frame

Available beginning 3 months and ending 5 years following article publication.

IPD Sharing Access Criteria

Requests should be directed to the corresponding author via email. De-identified individual participant data will be shared with researchers whose proposed use of the data has been approved by the principal investigator and institutional ethics committee, upon the establishment of a signed data access agreement.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe